The 2025-2030 World Outlook for Mood Stabilizers for Bipolar Disorders - Image 1

Out of Stock

This item is currently unavailable

The 2025-2030 World Outlook for Mood Stabilizers for Bipolar Disorders

Subjects

Out of Stock

Price data last checked 125 day(s) ago - refreshing...

View at Amazon

One email. No newsletter. No nudges.

Gone for 125 days. Could come back at any time — we're watching for you.

Out of stock 125 days · longest previous gap was 1 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

No Price Data Available

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

This study covers the world outlook for mood stabilizers for bipolar disorders across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of mood stabilizers for bipolar disorders as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis International, Otsuka Pharmaceutical Company, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZ2LQT49
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 29 April 2024

The 2025-2030 World Outlook for Mood Stabilizers for Bipolar Disorders

Gone for 125 days. Could come back at any time — we're watching for you.

Price History & Forecast

No Price Data Available

Price Distribution

Description

Product Specifications

Similar Products You Might Like

The 2026-2031 World Outlook for Mood Stabilizers for Bipolar Disorders

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

Symptom-Focused Psychiatric Drug Therapy for Managed Care: 12 (Routledge Library Editions: Psychiatry)

Meyler's Side Effects of Psychiatric Drugs

Integrating Psychotherapy and Psychopharmacology: A Handbook for Clinicians (Clinical Topics in Psychology and Psychiatry)

American Psychiatric Association Publishing Textbook of Psychopharmacology: Dsm-5 Edition

Handbook of Clinical Psychopharmacology for Therapists (Tenth Edition)

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

Stahl's Illustrated Mood Stabilizers

The Therapist's Guide to Psychopharmacology, Third Edition: Working with Patients, Families, and Physicians to Optimize Care

The Therapist's Guide to Psychopharmacology, Third Edition: Working with Patients, Families, and Physicians to Optimize Care

Psychopharmacologie essentielle. Le guide du prescripteur (3e édition française): (traduction de la 6e édition américaine)

Neuro-Psychopharmaka. Ein Therapie-Handbuch

Prescribing Mental Health Medication: The Practitioner's Guide

Pediatric Psychopharmacology Evidence: A Clinician's Guide

Handbook of Practical Psychopharmacology

Nurses' Clinical Consult to Psychopharmacology

The 2023-2028 World Outlook for Pain-Relieving Lidocaine Patches

The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)

Clinical Manual of Psychopharmacology in the Medically Ill

Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment

The American Psychiatric Association Publishing Textbook of Psychopharmacology, Sixth Edition: 1-2

The 2023-2028 Outlook for Drug Delivery Products for US Zip Codes

Neuro-Psychopharmaka Ein Therapie-Handbuch: Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer